88 related articles for article (PubMed ID: 15288150)
1. In search of the grail: the never-ending story of biomarkers for coronary risk prediction.
Sans S
Eur Heart J; 2004 Aug; 25(15):1271-3. PubMed ID: 15288150
[No Abstract] [Full Text] [Related]
2. Fibrinogen and coronary heart disease--what does it mean?
Oliver MF
Eur Heart J; 1998 Jan; 19(1):8-9. PubMed ID: 9503169
[No Abstract] [Full Text] [Related]
3. The role of inflammation for heart disease risk cannot be determined by correlations between C-reactive protein and risk factors.
Engström G
Arch Intern Med; 2006 May; 166(9):1040; author reply 1040-1. PubMed ID: 16682580
[No Abstract] [Full Text] [Related]
4. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease.
Nozaki T; Sugiyama S; Koga H; Sugamura K; Ohba K; Matsuzawa Y; Sumida H; Matsui K; Jinnouchi H; Ogawa H
J Am Coll Cardiol; 2009 Aug; 54(7):601-8. PubMed ID: 19660689
[TBL] [Abstract][Full Text] [Related]
5. Is adiponectin and its genetic regulators useful or not for prediction of carotid intima-media thickness and coronary heart disease?
Nilsson PM
Eur Heart J; 2008 Feb; 29(3):293-5. PubMed ID: 18174203
[No Abstract] [Full Text] [Related]
6. Soluble intercellular adhesion molecules, soluble vascular cell adhesion molecules, and risk of coronary heart disease.
Shai I; Pischon T; Hu FB; Ascherio A; Rifai N; Rimm EB
Obesity (Silver Spring); 2006 Nov; 14(11):2099-106. PubMed ID: 17135628
[TBL] [Abstract][Full Text] [Related]
7. Circulating biomarkers in acute coronary syndromes: something different or more of the same?
Keaney JF
Circulation; 2005 Aug; 112(6):778-80. PubMed ID: 16087806
[No Abstract] [Full Text] [Related]
8. [Should apolipoproteins be the first choice in routine health care?].
Järhult B; Lindström K
Lakartidningen; 2007 Oct 17-23; 104(42):3124. PubMed ID: 17985715
[No Abstract] [Full Text] [Related]
9. The time for cardiovascular inflammation reduction trials has arrived: how low to go for hsCRP?
Ridker PM
Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1222-4. PubMed ID: 18565847
[No Abstract] [Full Text] [Related]
10. [Effect of respiratory infections on the clinical course of coronary artery disease].
Lobzin IuV; Boĭtsov SA; Filippov AE; Linchak RM; Mangutov DA
Klin Med (Mosk); 2005; 83(11):22-6. PubMed ID: 16404934
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein complexed C-reactive protein in patients with coronary heart disease.
Elmas E; Kälsch T; Borggrefe M; Dempfle CE
Thromb Haemost; 2005 Nov; 94(5):1111-2. PubMed ID: 16363260
[No Abstract] [Full Text] [Related]
12. Re: "plasma fluorescent oxidation products as potential markers of oxidative stress for epidemiologic studies".
Meerwaldt R; Links T; Zeebregts C; Smit A
Am J Epidemiol; 2008 Mar; 167(6):756-7. PubMed ID: 18296707
[No Abstract] [Full Text] [Related]
13. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study.
Blankenberg S; McQueen MJ; Smieja M; Pogue J; Balion C; Lonn E; Rupprecht HJ; Bickel C; Tiret L; Cambien F; Gerstein H; Münzel T; Yusuf S;
Circulation; 2006 Jul; 114(3):201-8. PubMed ID: 16831981
[TBL] [Abstract][Full Text] [Related]
14. Association of European population levels of thrombotic and inflammatory factors with risk of coronary heart disease: the MONICA Optional Haemostasis Study.
Yarnell J; McCrum E; Rumley A; Patterson C; Salomaa V; Lowe G; Evans A
Eur Heart J; 2005 Feb; 26(4):332-42; discussion 317-8. PubMed ID: 15618045
[TBL] [Abstract][Full Text] [Related]
15. [Acute coronary syndrome and inflammation. Biomarkers for diagnostics and risk stratification].
Trepels T; Zeiher AM; Fichtlscherer S
Herz; 2004 Dec; 29(8):769-76. PubMed ID: 15599673
[TBL] [Abstract][Full Text] [Related]
16. [C-reactive protein in patients with coronary heart disease].
Rajtar R; Kolasińska-Kloch W; Kloch M
Folia Med Cracov; 2004; 45(1-2):25-32. PubMed ID: 16276823
[TBL] [Abstract][Full Text] [Related]
17. Contributions of depressive mood and circulating inflammatory markers to coronary heart disease in healthy European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME).
Empana JP; Sykes DH; Luc G; Juhan-Vague I; Arveiler D; Ferrieres J; Amouyel P; Bingham A; Montaye M; Ruidavets JB; Haas B; Evans A; Jouven X; Ducimetiere P;
Circulation; 2005 May; 111(18):2299-305. PubMed ID: 15867179
[TBL] [Abstract][Full Text] [Related]
18. Is LDL-C passed its prime? The emerging role of non-HDL, LDL-P, and ApoB in CHD risk assessment.
Davidson MH
Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1582-3. PubMed ID: 18716322
[No Abstract] [Full Text] [Related]
19. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
Ray KK; Cannon CP; Cairns R; Morrow DA; Ridker PM; Braunwald E
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):424-30. PubMed ID: 19122170
[TBL] [Abstract][Full Text] [Related]
20. Emerging cardiac markers in coronary disease: role of brain natriuretic peptide and other biomarkers.
Palazzuoli A; Iovine F; Gallotta M; Nuti R
Minerva Cardioangiol; 2007 Aug; 55(4):491-6. PubMed ID: 17653025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
